DNLI - Denali Therapeutics GAAP EPS of -$0.67 beats by $0.13
2025-02-27 16:47:01 ET
More on Denali Therapeutics
- Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
- Denali Therapeutics gets FDA breakthrough therapy designation for its treatment of hunter syndrome
- Denali ALS candidate fails in key study
- Seeking Alpha’s Quant Rating on Denali Therapeutics
- Historical earnings data for Denali Therapeutics